Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema
“We are thrilled to have started dosing patients with suprachoroidal OXU-001 in our OXEYE clinical trial, which will evaluate the potential for once-a-year treatment by leveraging our Oxusphere™ sustained-release technology.
- “We are thrilled to have started dosing patients with suprachoroidal OXU-001 in our OXEYE clinical trial, which will evaluate the potential for once-a-year treatment by leveraging our Oxusphere™ sustained-release technology.
- OXEYE builds on the positive clinical experience to date with our Oxulumis® illuminated microcatheter for in-clinic posterior suprachoroidal delivery,” said Dr. Friedrich Asmus, MD, Chief Medical Officer of Oxular.
- We look forward to clinical data from the OXEYE trial next year.”
OXU-001 is dexamethasone formulated in a novel biodegradable drug preparation known as Oxuspheres™. - The OXEYE trial is a two-part, randomized Phase 2 trial in patients with DME that is designed to evaluate a single administration of suprachoroidal OXU-001 over 52 weeks.